OSLO, Norway, Feb. 4, 2011 /PRNewswire/ — Photocure (OSE: PHO),
a Norwegian specialty pharmaceutical company focused in dermatology
and cancer, today announced positive results from its consumer
trial with Allumera™, a breakthrough cosmetic treatment
formulated to improve the skin’s appearance.
The RevitAll study was performed with a standard cosmetic
protocol and designed to confirm if treatment with Allumera™
improves skin appearance, when compared to exposure by light alone.
The study also looked into longevity of results.
This controlled, prospective study enrolled 120 women to receive
three treatments, four weeks apart. The total
duration of the study was five months. Half the study
participants received Allumera™ plus light, while the
remaining received light alone (control group). Participants
were monitored for three months following the last treatment to
evaluate which effects were long-lasting. The study
evaluations included both objective and subjective assessments.
The objective assessments included measurement of pores, skin
firmness/elasticity, skin tone (radiance/luminosity), skin surface
topography and tolerability.
At the five month evaluation, participants who received
Allumera™ for one hour followed by exposure to light, showed
a significant 44% reduction in the appearance of pores
(p<0.001), when compared to baseline, and the difference between
the two groups was statistically significant (p=0.002). A
statistically significant improvement (p<0.0001) in skin
firmness and suppleness was also observed for the Allumera group
when compared to the control group. A 35% improvement in the
appearance of skin tone (p<0.05) was also found, but this,
however, was not statistically significant when compared to the
control group.
“The results from our RevitAll study provide a solid foundation
for our efforts to commer
‘/>”/>
